Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Use of Information Technology in the Prevention of Diabetes
This study is not yet open for participant recruitment.
Verified by India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals, January 2009
Sponsors and Collaborators: India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals
Imperial College, United Kingdom- India Education and Research Intiative(UKIERI, World Diabetes Foundation
Information provided by: India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals
ClinicalTrials.gov Identifier: NCT00819455
  Purpose

Type 2 diabetes is a major and increasing problem in India and the UK. In clinical trials it can be prevented in people at high risk by lifestyle intervention. While these trials established the proof of principle, they involved a degree of input from healthcare professionals not feasible outside the trial situation. We hypothesise that diabetes prevention can be achieved at lower cost using personalised feedback via mobile phone, based on information on body weight, diet and physical activity. We shall develop research protocols and computerised algorithms to test this hypothesis in India for application subsequently in the UK and elsewhere.


Condition Intervention
Type 2 Diabetes
Behavioral: Experimental
Behavioral: Control arm (usual care/standard care arm)

MedlinePlus related topics: Diabetes
U.S. FDA Resources
Study Type: Interventional
Study Design: Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study
Official Title: The Role of Information Technology in the Prevention of Type 2 Diabetes

Further study details as provided by India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals:

Primary Outcome Measures:
  • Reduction in the incidence of diabetes. [ Time Frame: At intervals of six months for two years ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Improvement in metabolic risk factors for diabetes and cardiovascular diseases and improvement in quality of life [ Time Frame: two years ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 440
Study Start Date: March 2009
Estimated Study Completion Date: March 2012
Estimated Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
2: Active Comparator
Life style advice only once(Conventional life style advice)
Behavioral: Control arm (usual care/standard care arm)
Life style modification only once
1: Experimental
Active Life Style Modification
Behavioral: Experimental
Active Life style modification-motivation by I.T technology

Detailed Description:

The project will begin with the diabetes awareness campaign, using posters and pamphlets designed for the Indian population. Following implementation of the awareness campaign in selected workplace, employees will be selected for the prevention programme if they fulfil the following criteria: body mass index ≥ 23; age ≥ 35 years; a 1st degree relative with type 2 diabetes; and absence of other illness. The eligible subjects will undergo an OGTT with samples for glucose estimation at 0 and 2 hours. If the 2-hour plasma glucose level is > 7.8 - <11.1 mmol/l and/or the fasting glucose is >6.1 - <7.0 mmol/l, they will be selected for the project.

Participants will undergo randomization to either; the intervention group which will receive individualized feedback on lifestyle modification (diet and physical activity) by mobile phone or using their home computer; a control group which will receive conventional lifestyle advice.

The intervention group will be offered a mobile phone for the duration of the study (24 months). Their phone contract will be paid and payment will be provided for all calls and SMS messages sent or received for the purposes of the project. SMS messages will be sent each week and participants will be contacted monthly by voice, at times convenient to them, to discuss their progress and compliance with the behavioural modification. At 3 months, the participants in the intervention group will be contacted by phone and asked their views as to the frequency and mode of contact (SMS, voice contact or email). The advice will then be further individualized. The intervention group will have contact numbers for the investigators and may call or text at any time. The investigators will reply to messages within 48 hrs.

The participants will be seen baseline and at 6, 12, 18 and 24 months. Baseline assessments: Subjects will have a personal interview, complete a short health questionnaire and undergo a brief physical examination (including body weight, fat%,height, waist circumference, heart rate and blood pressure). They will complete questionnaires on diet and physical activity, quality of life and health care usage. A fasting blood sample will be taken for measurement of glucose, total and HDL-cholesterol, triglyceride, insulin, liver function, uric acid and other cardiovascular risk factors. An OGTT will be performed with samples for glucose and insulin estimation at 30 and 120 minutes. An ECG will be performed.

6 & 18 month assessments: Diet and physical activity questionnaires, body weight, WC, pulse and BP will be obtained. Two hour post prandial capillary glucose will be measured.

12 & 24 month assessment: Participants will be questioned about the acceptability of the project and its impact on their life. Changes in health will be documented and the physical examination repeated. They will complete further dietary, physical activity and quality of life questionnaires and will be asked about their use of healthcare resources for health economic assessment. The OGTT and ECG will be repeated, with other measurements as at baseline.

  Eligibility

Ages Eligible for Study:   35 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Body mass index ≥ 23
  • Age ≥ 35 years
  • A 1st degree relative with type 2 diabetes

Exclusion Criteria:

  • Normal and diabetic subjects
  • Presence of other serious illness
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00819455

Contacts
Contact: Ambady Ramachandran, M.D, D.Sc +91-44-28582003/04/05 ext 233 ramachandran@ardiabetes.org
Contact: Chamakuttan Snehalatha, M.Sc, D.Sc +91-44-28582003/04/05 ext 233 snehalatha@vsnl.com

Locations
India, TamilNadu
Dr.Ambady Ramachandran
Chennai, TamilNadu, India, 600 008
Dr.Ambady Ramachandran
Chennai, TamilNadu, India, 600 008
Sponsors and Collaborators
India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals
Imperial College, United Kingdom- India Education and Research Intiative(UKIERI, World Diabetes Foundation
Investigators
Principal Investigator: Ambady Ramachandran, M.D, D.Sc President, India Diabetes Research Foundation and Chairman & Managing Director, Dr.A.Ramachandran's Diabetes Hospitals
Principal Investigator: Desmond Geoffrey Johnston, MB Ch B, Ph.D Professor of Clinical Endocrinology, Imperial College, London
Study Director: Shaukat Sadikot, Doctor President, Diabetes India, 308, Doctor House, Peddar Road, Mumbai-400026, India
Study Director: Chittaranjan Sakerlal Yagnik, Doctor Director, Diabetes Unit, King Edward Memorial Hospital, Rastapet, Pune 411011, India
  More Information

Related Info  This link exits the ClinicalTrials.gov site

Responsible Party: Dr.A.Ramachandran, President and Prof. Desmond Geoffrey Johnston, Professor of Clinical Endocrinology ( Dr.A.Ramachandran, President and Prof. Desmond Geoffrey Johnston, Professor of Clinical Endocrinology )
Study ID Numbers: IT001IDRF-IC
Study First Received: January 8, 2009
Last Updated: January 14, 2009
ClinicalTrials.gov Identifier: NCT00819455  
Health Authority: India: Institutional Review Board

Keywords provided by India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals:
Diabetes
Prevention of Diabetes
Life Style Modification
Primary Prevention

Study placed in the following topic categories:
Metabolic Diseases
Diabetes Mellitus, Type 2
Diabetes Mellitus
Endocrine System Diseases
Endocrinopathy
Metabolic disorder
Glucose Metabolism Disorders

ClinicalTrials.gov processed this record on January 16, 2009